Company’s 36-month beta value is 0.14.Analysts have differing opinions on the stock, with 3 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for IRD is 25.80M, and currently, short sellers hold a 3.08% ratio of that floaft. The average trading volume of IRD on January 14, 2025 was 227.20K shares.
IRD) stock’s latest price update
Opus Genetics Inc (NASDAQ: IRD) has experienced a decline in its stock price by -14.79 compared to its previous closing price of 1.42. However, the company has seen a fall of -10.37% in its stock price over the last five trading days. globenewswire.com reported 2024-12-19 that Agreement Reached on Primary Endpoint and Phase 3 Trial Design Oral APX3330 is a Late-Stage Clinical Asset Available for Partnering FARMINGTON HILLS, Mich., Dec. 19, 2024 (GLOBE NEWSWIRE) — Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biotechnology company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small-molecule drugs to treat other ophthalmologic disorders, today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for a Phase 3 clinical trial evaluating oral APX3330 for the treatment of moderate to severe non-proliferative diabetic retinopathy (NPDR).
IRD’s Market Performance
IRD’s stock has fallen by -10.37% in the past week, with a monthly rise of 0.83% and a quarterly drop of -1.63%. The volatility ratio for the week is 11.24% while the volatility levels for the last 30 days are 11.54% for Opus Genetics Inc The simple moving average for the last 20 days is 5.09% for IRD’s stock, with a simple moving average of -17.80% for the last 200 days.
Analysts’ Opinion of IRD
Many brokerage firms have already submitted their reports for IRD stocks, with H.C. Wainwright repeating the rating for IRD by listing it as a “Buy.” The predicted price for IRD in the upcoming period, according to H.C. Wainwright is $8 based on the research report published on November 13, 2024 of the previous year 2024.
IRD Trading at 7.37% from the 50-Day Moving Average
After a stumble in the market that brought IRD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -63.44% of loss for the given period.
Volatility was left at 11.54%, however, over the last 30 days, the volatility rate increased by 11.24%, as shares surge +0.83% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -9.02% lower at present.
During the last 5 trading sessions, IRD fell by -10.37%, which changed the moving average for the period of 200-days by -40.39% in comparison to the 20-day moving average, which settled at $1.1514. In addition, Opus Genetics Inc saw 1.68% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IRD starting from Magrath George, who purchase 100,000 shares at the price of $0.98 back on Dec 26 ’24. After this action, Magrath George now owns 599,150 shares of Opus Genetics Inc, valued at $97,600 using the latest closing price.
YERXA BENJAMIN R, the President of Opus Genetics Inc, purchase 10,000 shares at $0.98 during a trade that took place back on Nov 21 ’24, which means that YERXA BENJAMIN R is holding 342,800 shares at $9,834 based on the most recent closing price.
Stock Fundamentals for IRD
Equity return is now at value -64.30, with -57.50 for asset returns.
The liquidity ratio also appears to be rather interesting for investors as it stands at 6.63.
Conclusion
In a nutshell, Opus Genetics Inc (IRD) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
